共 50 条
- [21] A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantationSupportive Care in Cancer, 2018, 26 : 1013 - 1016Julia ZecchiniKendra YumAmir SteinbergCardinale SmithSara Kim
- [22] Prophylaxis of chemotherapy-induced febrile neutropenia with biosimilar filgrastim: Description of patients, treatment patterns and outcomes in the MONITOR-GCSF Study in GermanyONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 161 - 161Bokemeyer, C.Ottillinger, B.Bulenda, D.Turner, M.
- [23] Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Li, Edward C.Mezzio, DylanSpargo, AndrewCampbell, Kimberley J.Lyman, Gary H.
- [24] Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric studySupportive Care in Cancer, 2016, 24 : 1991 - 1998Sophie NahonMansour RastkhahMeher Ben AbdelghaniRavaka-Fatoma SoumoudrongaIsabelle GasnereauJean-Luc Labourey
- [25] ZarzioA®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric studySUPPORTIVE CARE IN CANCER, 2016, 24 (05) : 1991 - 1998Nahon, SophieRastkhah, MansourBen Abdelghani, MeherSoumoudronga, Ravaka-FatomaGasnereau, IsabelleLabourey, Jean-Luc
- [26] Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083-93JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (06) : 603 - 605Bensink, MarkEdwards, ChristineBowers, CharlesCampbell, Jon
- [27] Treatment patterns and outcomes in patients with breast cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropenia: Results from the MONITOR-GCSF studyEUROPEAN JOURNAL OF CANCER, 2018, 92 : S53 - S53Aapro, M.Krendyukov, A.Krivtsova, N.Gascon, P.
- [29] Prophylaxis of chemotherapy-induced febrile neutropenia with biosimilar filgrastim: Description of patients, treatment patterns and outcomes in the MONITOR-GCSF study in the breast cancer cohortCANCER RESEARCH, 2015, 75Gascon, PereAapro, MattiLudwig, HeinzBoccadoro, MarioBokemeyer, CarstenTurner, MatthewMuenzberg, MichaelAbraham, IvoDenhaerynck, KrisMacDonald, Karen
- [30] Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in solid tumours versus haematological malignancies: Patterns, outcomes and determinants (MONITOR-GCSF study)ANNALS OF ONCOLOGY, 2017, 28Aapro, M.Bokemeyer, C.Boccadoro, M.Gascon, P.Denhaerynck, K.Krendyukov, A.Abraham, I.Macdonald, K.Ludwig, H.